294.82 +0.77 (0.26%)
After hours: 7:30PM EST
|Bid||294.26 x 800|
|Ask||294.26 x 800|
|Day's Range||275.01 - 295.02|
|52 Week Range||107.44 - 306.71|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||267.32|
|Earnings Date||Apr 28, 2020 - May 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||292.60|
This agreement is a major step forward in Insulet's (PODD) commitment toward bolstering its automated insulin delivery system and providing better clinical outcomes for diabetes patients.
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Dexcom and Insulet Announce Commercial Agreement
Dexcom stock rocketed to a record high Friday after the diabetes treatment outlet topped its pre-announced fourth-quarter revenue by $6 million. Analysts are bullish on the stock.
The major stock indexes were mixed early Friday after U.S. retail sales. Nvidia, Roku and Dexcom soared on earnings results.
Several Dexcom analysts raised their share-price targets for the diabetes-treatment company after its fourth-quarter earnings beat Wall Street's estimates.
Dow Jones futures rose modestly early Friday, along with S&P 500 futures and Nasdaq futures, after the stock market rally held its ground Thursday. Nvidia, Dexcom, Roku, Datadog and Alteryx reported earnings after the close.
Dexcom stock popped Thursday after the diabetes treatment outlet crushed Wall Street's fourth-quarter earnings forecasts. The company also offered better-than-expected sales guidance.
The Zacks Analyst Blog Highlights: Waste Management, TC Energy, Duke Energy, DexCom and Republic Services
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
Although corporate earnings growth was negative year over year in the first three quarters of last year, fourth-quarter results have been faring better than initially anticipated.